Gujarat Kidney Super Speciality Ltd vs Modern Diagnostic Research Centre Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 163.5 as of 30 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Modern Diagnostic & Research Centre Ltd changed from 0 on March 2023 to 0 on March 2026 . This represents a CAGR of 0.0% over 4 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Modern Diagnostic & Research Centre Ltd changed from ₹ 0 crore on March 2023 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 4 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Modern Diagnostic & Research Centre Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Modern Diagnostic & Research Centre Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 8 quarters. This represents a CAGR of 34.06% The net profit of Modern Diagnostic & Research Centre Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Modern Diagnostic & Research Centre Ltd changed from 0 % on March 2023 to 0 % on March 2022 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Modern Diagnostic & Research Centre Ltd

The Promoter, Mr. Devendra Singh Yadav started its operations of Diagnostic Centre in the name and style of 'Modern X-Ray and Clinical Lab' as Proprietorship firm in year 1985, which was later designated as 'Modern Diagnostic & Research Centre' in 1992.
Modern Diagnostic & Research Centre Limited was erstwhile incorporated as 'Modern Diagnostic & Research Centre Private Limited' as a private company, vide Certificate of Incorporation dated April 16, 2012 issued by Registrar of Companies, Delhi . Thereafter, the Company acquired the business of M/s.
Modern Diagnostics & Research Centre, a Proprietorship Concern through Business Transfer Agreement in 2013.
Subsequently, its status got converted from private limited into public limited and the name of the Company was changed to 'Modern Diagnostic & Research Centre Limited' pursuant to fresh certificate of incorporation dated December 18, 2024 issued by Registrar of Companies, Central Processing Centre.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Modern Diagnostic & Research Centre Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Modern Diagnostic & Research Centre Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,289 Cr while Market cap of Modern Diagnostic & Research Centre Ltd is 87 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Modern Diagnostic & Research Centre Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Modern Diagnostic & Research Centre Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Modern Diagnostic & Research Centre Ltd?

As of November 1, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹163.5. On the other hand, Modern Diagnostic & Research Centre Ltd stock price is INR ₹58.0.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Modern Diagnostic & Research Centre Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Modern Diagnostic & Research Centre Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.